Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) – Research analysts at Oppenheimer Holdings issued their FY2017 EPS estimates for Sunesis Pharmaceuticals in a report issued on Monday. Oppenheimer Holdings analyst H. Singh anticipates that the biopharmaceutical company will earn ($1.60) per share for the year. Oppenheimer Holdings currently has a “Outperform” rating and a $7.00 target price on the stock. Oppenheimer Holdings also issued estimates for Sunesis Pharmaceuticals’ Q4 2017 earnings at ($0.33) EPS, FY2018 earnings at ($0.91) EPS, FY2019 earnings at ($1.01) EPS and FY2020 earnings at ($1.12) EPS.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.06). During the same period last year, the firm earned ($0.62) earnings per share.

Several other research analysts have also recently issued reports on the company. ValuEngine cut Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research cut Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Cowen Inc reaffirmed a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Thursday, November 2nd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $3.00 price objective on shares of Sunesis Pharmaceuticals in a research report on Wednesday, September 27th. Finally, UBS AG began coverage on Sunesis Pharmaceuticals in a research report on Monday, November 20th. They set an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $4.17.

Sunesis Pharmaceuticals (SNSS) opened at $2.97 on Thursday. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of -0.34. Sunesis Pharmaceuticals has a 12-month low of $1.82 and a 12-month high of $4.45.

Several hedge funds have recently bought and sold shares of SNSS. Renaissance Technologies LLC raised its stake in Sunesis Pharmaceuticals by 1.1% during the 1st quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after purchasing an additional 1,230 shares during the period. Sphera Funds Management LTD. raised its stake in Sunesis Pharmaceuticals by 54.6% during the 2nd quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 68,212 shares during the period. Wells Fargo & Company MN raised its stake in Sunesis Pharmaceuticals by 77.4% during the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 18,254 shares during the period. Vanguard Group Inc. raised its stake in Sunesis Pharmaceuticals by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after purchasing an additional 23,819 shares during the period. Finally, Virtu KCG Holdings LLC bought a new stake in Sunesis Pharmaceuticals during the 2nd quarter valued at approximately $208,000. 39.43% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Dayton Misfeldt acquired 400,000 shares of the stock in a transaction dated Friday, October 27th. The shares were purchased at an average cost of $2.00 per share, with a total value of $800,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Mpm Oncology Impact Management acquired 81,500 shares of the stock in a transaction dated Monday, November 6th. The shares were bought at an average cost of $2.77 per share, for a total transaction of $225,755.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 506,800 shares of company stock worth $1,091,282. Insiders own 10.21% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/11/25/research-analysts-issue-forecasts-for-sunesis-pharmaceuticals-inc-s-fy2017-earnings-snss.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Stock Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.